Bank of America reiterated their neutral rating on shares of Rockwell Medical (NASDAQ:RMTI) in a research report sent to investors on Wednesday morning, Market Beat reports.

RMTI has been the subject of a number of other recent research reports. Analysts at Oppenheimer set a $26.00 price target on shares of Rockwell Medical and gave the company a buy rating in a research note on Monday, June 22nd. Separately, analysts at Zacks upgraded shares of Rockwell Medical from a sell rating to a hold rating in a research note on Friday, May 8th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. Rockwell Medical currently has a consensus rating of Hold and a consensus target price of $17.17.

Shares of Rockwell Medical (NASDAQ:RMTI) traded down 2.46% during mid-day trading on Wednesday, hitting $16.24. 463,096 shares of the company’s stock traded hands. Rockwell Medical has a 52-week low of $8.10 and a 52-week high of $18.04. The stock’s 50-day moving average is $13.32 and its 200-day moving average is $11.16. The company’s market cap is $816.37 million.

Rockwell Medical (NASDAQ:RMTI) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.03. The company had revenue of $13.90 million for the quarter, compared to the consensus estimate of $13.20 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share. The company’s revenue for the quarter was up 6.9% on a year-over-year basis. On average, analysts predict that Rockwell Medical will post $-0.08 earnings per share for the current fiscal year.

Rockwell Medical, Inc. (NASDAQ:RMTI) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company’s lead branded drug, Triferic is approved by the United States Food and Drug Administration (FDA). Triferic is an iron compound that is delivered to hemodialysis patients via dialysate, replacing the iron loss that occurs during their dialysis treatment. Triferic enters the blood and immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. Rockwell’s generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. The Company manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.

...